← Browse by Condition
Medical Condition

myeloproliferative neoplasm

Total Trials
3
Recruiting Now
3
Trial Phases
Phase 2, Phase 3

ClinicalMetric tracks all active clinical trials for myeloproliferative neoplasm sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — myeloproliferative neoplasm Clinical Trials

How many clinical trials are currently recruiting for myeloproliferative neoplasm?
ClinicalMetric currently tracks 3 actively recruiting clinical trials for myeloproliferative neoplasm, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 3. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for myeloproliferative neoplasm?
myeloproliferative neoplasm research spans Phase 2 (2 trials), Phase 3 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a myeloproliferative neoplasm clinical trial?
Eligibility criteria for myeloproliferative neoplasm trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 2
2
Phase 3
1
Top Sponsors
City of Hope Medical Center 2 trials
PharmaEssentia 1 trial

Recruiting Clinical Trials

NCT06815003 Phase 2
Recruiting
Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning
Enrollment
35 pts
Location
United States
Sponsor
City of Hope Medical Center
View Trial →
NCT06059391 Phase 2
Recruiting
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
Enrollment
216 pts
Location
United States
Sponsor
City of Hope Medical Center
View Trial →
NCT06468033 Phase 3
Recruiting
P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk
Enrollment
150 pts
Location
Japan
Sponsor
PharmaEssentia
View Trial →

Related Conditions

acute lymphoblastic leukemia (2) acute myeloid leukemia (2) myelodysplastic syndrome (2) chronic myelomonocytic leukemia (1) graft versus host disease (1) chronic lymphocytic leukemia (1) chronic myeloid leukemia bcr abl1 positive (1) hematopoietic and lymphoid system neoplasm (1) hodgkin lymphoma (1) myelofibrosis (1) non hodgkin lymphoma (1) primary myelofibrosis (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology